A compound or a pharmaceutically acceptable salt thereof of Formula VI or Formula VII: or wherein R 1 is selected from the group consisting of H, lower alkyl, and aryl, wherein when R 1 is not H, R 1 is lower alkyl or an aryl substituted with 0-2 radicals each independently selected from the group consisting of H, a halogen, a hydroxyl, -OR 11, -SR 11, lower alkyl,-CO 2 R 11, -OC R 11, -NR 10 COR 11, -CONR 11, -NR 11 C NR 11 R 11, -OC NR 11 R 11,-NR 11 C OR 11, and imidazolyl, wherein R 10 is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, and cyclopropylmethyl, and wherein each R 11 is independently selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, and cyclopropylmethyl and when a nitrogen associated with R 11 is substituted with two non-hydrogen groups, the groups are independent or taken together to consist of a 5 or 6 membered ring; R 2 and R 3 together comprise a 4-6 member aliphatic, carbocyclic, or heterocyclic ring comprising 0, 1, or 2 heteroatoms, each heteroatom selected from the group consisting of N, O, and S; Y is selected from the group consisting of CH 2, O, and S; W is selected from the group consisting of O and S; R 9 is selected from the group consisting of H, lower alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, -CONR 8 R 8, and -CO 2 R 8 and R 9 is further substituted with 0-3 groups selected from the group consisting of a halogen, a hydroxyl, amine, lower alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyloalkyl, aryl, arylalkyl, -OR 8, -SR 8, -NR 8 R 8, -CONR 8 R 8, -NR 8 COR 8, -CO 2 R 8, -NR 8 C OR 8, and -NR 8 C NR 8 R 8, and wherein each R 8 is independently selected from the group consisting of H, lower alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, and arylalkyl; wherein, when R 9 comprises R 8 and N and the N is substituted with two non-hydrogen groups, the groups are independent or taken together to consist of a 5 or 6 membered ring;; and wherein lower alkyl is C 1 -C 10 linear alkyl, C 3 -C 10 branched alkyl, or C 3 -C 10 cyclic alkyl and 0, 1, 2 or 3 carbons of a lower alkyl are replaced with a heteroatom, each heteroatom being selected from the group consisting of N, O, and S; or a compound or a pharmaceutically acceptable salt thereof of structure selected from the group consisting of and wherein R 1 is selected from the group consisting of H, lower alkyl, and aryl, wherein when R 1 is not H, R 1 is lower alkyl or an aryl substituted with 0-2 radicals each independently selected from the group consisting of H, a halogen, a hydroxyl, -OR 11, -SR 11, lower alkyl,-CO 2 R 11, -OC R 11, -NR 10 COR 11, -CONR 11, -NR 11 C NR 11 R 11, -OC NR 11 R 11,-NR 11 C OR 11, and imidazolyl, wherein R 10 is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, and cyclopropylmethyl, and wherein each R 11 is independently selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, and cyclopropylmethyl and when a nitrogen associated with R 11 is substituted with two non-hydrogen groups, the groups are independent or taken together to consist of a 5 or 6 membered ring; R 2 and R 3 together comprise a 4-6 member aliphatic, carbocyclic, or heterocyclic ring comprising 0, 1, or 2 heteroatoms, each heteroatom selected from the group consisting of N, O, and S; Y is selected from the group consisting of CH 2, O, and S; W is selected from the group consisting of O and S; R 9 is selected from the group consisting of H, lower alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, -CONR 8 R 8, and -CO 2 R 8 and R 9 is further substituted with 0-3 groups selected from the group consisting of a halogen, a hydroxyl, amine, lower alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyloalkyl, aryl, arylalkyl, -OR 8, -SR 8, -NR 8 R 8, -CONR 8 R 8, -NR 8 COR 8, -CO 2 R 8, -NR 8 C OR 8, and -NR 8 C NR 8 R 8, and wherein each R 8 is independently selected from the group consisting of H, lower alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, and arylalkyl; wherein, when R 9 comprises R 8 and N and the N is substituted with two non-hydrogen groups, the groups are independent or taken together to consist of a 5 or 6 membered ring;; and wherein lower alkyl is C 1 -C 10 linear alkyl, C 3 -C 10 branched alkyl, or C 3 -C 10 cyclic alkyl and 0, 1, 2 or 3 carbons of a lower alkyl are replaced with a heteroatom, each heteroatom being selected from the group consisting of N, O, and S; or a compound or a pharmaceutically acceptable salt thereof of structure selected from the group consisting of and